CTLA4 and glioblastoma: In the high m6A scoring group despite higher immune checkpoint expression, GBM individuals responded poorly to anti-CTLA4 immunotherapy regimens due to dysfunctional T cells, whereas the low m6A scoring group had an immunodeficient phenotype with less immune cell infiltration and a better prognosis (160).